On this page
Overview
Product & regulatory status
US prescription products exist; confirm the indication and formulation on your own medicine label. Compounded preparations are not FDA-approved finished products.
GIP and GLP-1 signaling
Tirzepatide acts through GIP and GLP-1 receptors, influencing glucose regulation and appetite. A two-receptor mechanism does not by itself determine which treatment is best for an individual. [1]
What the evidence shows
Weight-management evidence
A randomized trial in adults with overweight or obesity studied weight change with this medicine alongside lifestyle intervention. Results apply to the studied population and treatment, not every formulation. [2]
SURMOUNT-1 · what was measured
This 72-week randomized trial enrolled 2,539 adults with obesity or overweight plus a related complication, excluding diabetes. Tirzepatide groups lost more weight than placebo; gastrointestinal events were common and some participants stopped treatment because of adverse events. Trial averages do not predict an individual result or validate a different preparation. [2]
What remains unknown
A group average does not predict an individual result. Other indications and formulations need their own evidence.
Safety
Important medicine precautions
Patient information includes a thyroid-tumor warning and precautions about pancreatitis, gallbladder problems, dehydration, and low blood sugar with some other medicines. Review the full information with your clinician. [1]
Device and storage details vary
Use the exact product leaflet for its pen or vial. Storage limits depend on the presentation and whether it has been opened. Do not transfer a storage period or device instruction from another tirzepatide product. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
What should I ask when comparing products?
A group average does not predict an individual result. Other indications and formulations need their own evidence.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Tirzepatide InjectionMedlinePlus · patient medicine information
- Tirzepatide Once Weekly for the Treatment of Obesity2022 · randomized human trial · PMID 35658024
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.